Global Adenoid Cystic Carcinoma Market - 2023-2030

Global Adenoid Cystic Carcinoma Market - 2023-2030

Global Adenoid Cystic Carcinoma Market reached US$ 224.3 million in 2022 and is expected to reach US$ 344.6 million by 2030 growing with a CAGR of 5.6% during the forecast period 2023-2030. The trend such as shift towards personalized medicine is expected to dominate the global adenoid cystic carcinoma market.

The global adenoid cystic carcinoma (ACC) market has grown significantly in recent years and is projected to continue on its upward trend. The market is undergoing a transformational period, influenced by several significant trends such as usage of targeted therapies, and emerging immunotherapy and RNA therapy options.

Furthermore, rising prevalence of adenoid cystic carcinoma, advancements in diagnostic techniques, increase in focus on research and development activities is driving up the adenoid cystic carcinoma market size. Due to the advancements of diagnostics technologies in these fields resulting improved detection and diagnosis of adenoid cystic carcinoma is seeing an increase in demand from North American regions with significant competitors like Ayala Pharmaceuticals, Amgen, CureVac AG, and others actively operating in the market.

Market Dynamics

The Growing Prevalence of Adenoid Cystic Carcinoma to Drive the Growth of the Adenoid Cystic Carcinoma Market

The rising number of cases of adenoid cystic carcinoma is a key driver driving the adenoid cystic carcinoma market's expansion. This is due to the increase awareness about the disease that has resulted in more number of cases. For instance, according to the American Society of Clinical Oncology (ASCO) report of 2023, about 1300 people are been diagnosed with this cancer every year in U.S.

Moreover, the adenoid cystic carcinoma is mostly prevalent in women accounting 60% of all cases. Because of this increasing occurrence, there has been a greater emphasis on the research and development, with the goal of discovering novel therapeutic options and improving existing medications. Thus, owing to the growing prevalence of these condition to drive the market over the forecast period.

The Increasing Number of Clinical Trials will Drive the Market Growth

The growing number of clinical trials for adenoid cystic carcinoma treatment and diagnosis is a major driver for this market. Clinical trials play a major role in discovering novel treatment and diagnostic options thereby providing a improved patient outcomes. Moreover, the data generated from this clinical trial makes an important gateway in fostering the research, and increasing the international collaboration.

For instance, Memorial Sloan Kettering Cancer Center in collaboration with Merck Sharp & Dohme LLC and Eisai Inc. is conducting a clinical trial that has began on December 2019. The primary objective of this trial is to evaluate the study and safety of drugs such as Lenvatinib and Pembrolizumab in people with advanced Adenoid Cystic Carcinoma (ACC). Currently the trial is phase 2 and the estimated completion of trial is December 2023. Thus, owing to the increasing number of clinical trials the market is expected to drive over the foreseeable future.

The High Cost Associated with Adenoid Cystic Carcinoma Treatment will Hamper the Growth of the Market

Adenoid cystic carcinoma treatment involves surgery, medication such as targeted therapies, that can be relatively expensive. This has resulted in limited access towards advanced treatment for the patient suffering from this condition. For instance, the cost of immunotherapy drugs used in ACC treatment are very costly for many patient, thereby hindering their access to this potentially beneficial treatment option.

Segment Analysis

The global adenoid cystic carcinoma market is segmented based on location, drug class, treatment, distribution channel and region.

Owing to its Better Effectiveness, the Surgery Segment Accounted for Approximately 34.6% of the Adenoid Cystic Carcinoma Market Share

The surgery segment is poised to dominate the adenoid cystic carcinoma market as it remains a common and preferred medical treatment for adenoid cystic carcinomas owing to its effectiveness and better cure for this carcinoma. As adenoid cystic carcinoma mainly affects in the salivary gland, the surgery remains the foremost treatment option for this disease. During surgery their is removal of tumor and some of the healthy tissue around the cancer, as this cancer spreads frequently along the nerves, the surgery becomes an important segment in identifying the nerves involved in it.

Furthermore, many clinical trial are in progress involving different surgery tecniques. For instance, Ohio State University Comprehensive Cancer Center is conducting a clinical trial consisting of transoral robotic surgery (TORS) for treating adenoid cystic carcinoma it uses the the Da Vinci Robotic Surgical System for the surgery. Furthermore, radiation therapy is advised after surgery if there is an intermediate- or high-grade cancer or an adenoid cystic carcinoma, or the cancer was not removed completely. Thus, considering the above factors the segment is expected to grow over the forecast period.

Geographical Penetration

North America Accounted for Approximately 39.4% of the Market Share in 2022, Owing to the Presence of Renowed Research Institutions

North America, particularly the United States, dominates the global adenoid cystic carcinoma market due to its advanced healthcare infrastructure, presence of renowed research institute conducting research for development of novel treatment options. The region's superior medical facilities provide access to cutting-edge therapies, while intensive awareness campaigns and regular screenings contribute to improved early identification and treatment outcomes.

For instance, a 2022 article published in American Society of Clinical Oncology the University of Texas MD Anderson Cancer Center an established research center in U.S. has conducted a extensive research for this carcinoma. The research involves use of NOTCH1 inhibitors that targets NOTCH1-mutant adenoid cystic carcinoma. These inhibitors are designed from sequencing techniques and molecular analysis, that shows immense promise for patients with ACC, a rare and aggressive head and neck cancer. Therefore, owing to the above factors the market is expected to grow at faster rate in this region over the forecast period.

Competitive Landscape

The major global players in the adenoid cystic carcinoma include Ayala Pharmaceuticals, Amgen, CureVac AG, Elevar Therapeutics, Actuate Therapeutics, Prelude Therapeutics, Merck Sharp & Dohme Corp., Lilly USA, LLC, Celgene Corporation, and OncoMed Pharmaceuticals and among others.

COVID-19 Impact Analysis

The effect of COVID-19 on ACC has worsened the presenting stage of many malignancies and had a detrimental impact on their prognosis. However, rivoceranib, an oral VEGFR2 TKI, showed promising results in individuals with recurrent or metastatic ACC in a phase 2 study. COVID-19 may have an extensive effect on the standard of life and well-being of cancer patients and survivors.

Moreover, cancer patients, such as those with ACC, are more likely to develop severe COVID-19 and die from it, especially if they are older, male, have a larger number of comorbidities, have hematologic malignancies, and have just received chemotherapy. Cancer screening delays during the pandemic led to delayed detection, a higher proportion of patients being diagnosed at an advanced stage, and a higher death rate. ACC patients must adhere to strict follow-up and seek medical attention for any suspicious clinical signs since early detection improves illness prognosis.

Russia Ukraine Conflict Analysis

The Russia-Ukraine conflict is having impact on the global adenoid cystic carcinoma market. The conflict has decreased access to healthcare services in Ukraine, making it harder for adenoid cystic carcinoma patients to receive critical treatment. The increased financial load on patients as a result of treatment costs and economic instability has further hampered access to care. Delayed diagnosis and treatment have also been noted as people are unwilling to seek medical help in the midst of the conflict.

These obstacles have had a detrimental impact on the worldwide adenoid cystic carcinoma market, producing slower growth than expected. However, there is potential for development, such as a greater emphasis on creating more effective treatment options and improving adenoid cystic carcinoma awareness in Ukraine. As the war ends and healthcare access improves, the market is projected to rebound. Nonetheless, the conflict's impact on the market is still enormous, necessitating continual efforts to handle the problems and opportunities it brings.

By Site
• Salivary Gland
• Lacrimal Gland
• Breast
• Others

By Drug Class
• Cytotoxic Drugs
• Tyrosine Kinase Inhibitors
• Monoclonal Antibodies
• Others

By Treatment
• Surgery
• Radiation Therapy
• Chemotherapy
• Targeted Therapy

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Key Developments
• On June 6, 2022, Ayala Pharmaceuticals, Inc., a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, stated that data from the Phase 2 ACCURACY study will be presented in a poster at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting held on June 3-7, 2022, in Chicago, Illinois.
• On February 8, 2021, Elevar Therapeutics, Inc stated in a press release that the FDA has given Orphan Drug Designation to the small molecule tyrosine kinase inhibitor apatinib (Rivoceranib) for the treatment of the rare disease adenoid cystic carcinoma.

Why Purchase the Report?
• To visualize the global adenoid cystic carcinoma market segmentation based on location, drug class, treatment, distribution channel, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of adenoid cystic carcinoma market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available as excel consisting of key products of all the major players.

The global adenoid cystic carcinoma market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies